Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

Trusted source of information on diabetes that includes articles, news, videos, animations, quizzes, calculators and drugs.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...